Portfolio company
Boulevard Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This clinical-stage biotechnology company develops multi-specific antibody therapies for patients suffering from B cell-driven autoimmune diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Beeline Medicines
This clinical-stage biotechnology company develops precision therapies for patients living with autoimmune and inflammatory diseases.
Candid Therapeutics
This clinical-stage biotechnology company develops T-cell engager antibodies for patients with autoimmune and inflammatory diseases.
Attovia Therapeutics
The company develops biparatopic biologics to treat patients with immune-mediated diseases and cancer through a modular protein design platform.
EpiBiologics
This company develops bispecific antibodies to degrade extracellular proteins for patients with cancer and autoimmune disorders.
Granite Bio
This clinical-stage biotechnology company develops therapeutic antibodies to treat patients with inflammatory, autoimmune and fibrotic diseases.
Laigo Bio
This company develops bispecific antibody therapies that remove disease-causing membrane proteins to treat patients with cancer and autoimmune disorders.
Cabaletta Bio
This clinical-stage biotechnology company develops engineered T cell therapies for patients with various autoimmune diseases.
Re-Aim Therapeutics
This early-stage biotechnology company develops antibody-based therapies that target and deplete disease-causing cells to treat patients with autoimmune and inflammatory disorders.